glp-1 kidney function receptor agonists and next-generation metabolic hormone therapies in chronic disease CKJ REVIEW GLP-1 receptor agonists

But as their popularity grows, so does the research into long-term side effects of GLP-1 medications

Medullary thyroid carcinoma surveillance study: a case-series registry

Q: Is Semaglutide a replacement for diet and exercise

As many as 48 million Americans who want to lose weight expect to start a GLP-1 drug in 2026

The retatrutide versus tirzepatide debate involves fundamentally different mechanisms, different risk profiles, different timelines for access, and different metabolic benefits that extend well beyond body weight

With injections, blood levels of semaglutide and tirzepatide are consistent and measurable